On February 12, Shanghai Yizhong Pharmaceutical Co., Ltd. (hereinafter referred to as "Shanghai Yizhong") and Qingdao BAHEAL Pharmaceutical Co., Ltd. (hereinafter referred to as "BAHEAL Pharmaceutical") signed a cooperation agreement in Qingdao, and the two sides will cooperate on the commercialization of Shanghai Yizhong's innovative tumor drug "Paclitaxel Polymer Micelle for Injection" (hereinafter referred to as "paclitaxel Micelle") zisheng, jointly promoting the accessibility of domestic innovative tumor drugs and benefiting many cancer patients in China.
As the cornerstone drug of anti-tumor chemotherapy, paclitaxel products have a wide range of indications, accurate efficacy and large clinical needs, and are currently the most widely used anti-tumor chemotherapy blockbuster star drugs in China, which has been developed for 30 years.
Compared with other paclitaxel dosage forms on the market, paclitaxel micelles have relatively better safety in the case of a significant increase in the dose of clinical use, without any anti-allergic pretreatment before medication, without the use of special infusion devices, and the clinical use is convenient; clinical trial results for non-small cell lung cancer (NSCLC) show that the objective response rate (ORR) of paclitaxel micelles is significantly improved, and the progression-free survival (PFS) is significantly prolonged. In the first-line treatment of advanced non-small cell lung cancer, both the efficacy and safety have shown its unique advantages and advancedness, and will become a new choice for chemotherapy drugs for non-small cell lung cancer.
At the signing ceremony, Zhou Jinsong, chairman of Shanghai Yizhong, said: "Shanghai Yizhong is committed to developing a new generation of innovative drugs to provide patients with safe, effective and affordable high-quality drugs to meet the treatment needs that need to be solved urgently. Paclitaxel micellar is our first marketed product, and in the commercialization stage, we hope to cooperate with a professional third-party commercialization platform such as BAHEAL Pharmaceutical to jointly promote the entry of innovative drug products into the market and benefit more cancer patients. ”
Fu Gang, Chairman of BAHEAL Pharma, said: "As a third-party commercialization platform with brand operation as the core, BAHEAL Pharma has strict selection standards. The first is to choose products that can truly optimize clinical application scenarios, the second is to rely on professional evaluation capabilities to evaluate the technical barriers of products to avoid falling into a low-level duplication dilemma, and the third is to do a good job in element allocation with ecological collaboration, and select products that can truly complement and coordinate with BAHEAL resources for commercial operation. ”
"Paclitaxel micellar Zisheng is the third generation of paclitaxel, which has significant efficacy and good safety. BAHEAL Pharmaceutical will do a good job in the allocation of elements according to the characteristics of its life cycle, formulate reasonable commercialization solutions, and help products release value. Fu Gang further said.
The cooperation between Shanghai Yizhong and BAHEAL Pharmaceutical will integrate the strong research and development strength of innovative drugs and excellent commercialization capabilities of both sides, and the two sides will join hands and are expected to bring new cooperation examples to the field of innovative drug commercialization. (Chen Xiaoli)
![Poinsettia partners ar882 global clinical Phase II .b trial patients enrolled[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)